• Beatriz Napal, José David García-Palacios, Belén González-Mesones, José Javier Napal, and José Luis Hernández.
• Depto. de Medicina y Psiquiatría. Universidad de Cantabria, Santander, Spain.
• Med Clin (Barc). 2023 Sep 29; 161 (6): 231237231-237.

IntroductionRetinal vein occlusion (RVO) is mostly a consequence of vascular risk factors (VRF). COVID-19 vaccines have been related to vascular and thrombotic events (VTE).ObjectiveTo assess the RVO incidence in the general population in our health area and the possible relation with COVID-19 infection and vaccination.MethodsDemographic features, classic VRF, thrombophilia data, COVID-19 status, and Framingham risk score were collected prospectively.Results472 consecutive patients studied over 13 years with RVO were included (Valdecilla Cohort). Classic VRFs were present in 90%, antiphospholipid syndrome in 12.3%, and genetic thrombophilia in 13.5%. Ninety-one percent of RVO patients were vaccinated and 6.8% suffered COVID-19 infection. In the cohort, no patient had a new RVO after vaccination or infection. In the general population, 20 subjects had RVO after receiving the vaccine (0.006%). Overall, 8 cases occurred in the first-month post-vaccination and 12 after 30 days. In the early and late groups, there are 3 and 4 patients respectively, with a low-intermediate risk Framingham score. Twenty-nine patients in the cohort suffered SARS-CoV-2 infection, twenty-seven of them had RVO before infection. Two patients with low-risk Framingham scores had RVO after infection, one of them early (<1 month).ConclusionsVaccination and COVID-19 might be involved in the development of RVO in some cases, mainly in patients without VRF, thrombophilia, or chronic inflammatory conditions and with a lower Framingham score, especially in the first month after vaccination or infection.Copyright © 2023 Elsevier España, S.L.U. All rights reserved.

22 keywords...

hide…